drugset / Trial / NCT03103399
Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" Phenomenon
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study was to investigate the effect on the "wearing-off" phenomenon of 3 different doses of nebicapone (NEB 50 mg, 100 mg and 150 mg), compared with entacapone and placebo when dministered concomitantly with existing treatment with levodopa plus a dopa decarboxylase inhibitor (DDCI: carbidopa or benserazide).
Timeline
- Start
- 2006-09-26
- Primary completion
- 2007-09-21
- Completion
- 2007-09-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Entacapone | Small molecule | 200 mg | — |
| Subject | Nebicapone | Small molecule | 50 mg | — |
| Subject | Nebicapone | Small molecule | 100 mg | — |
| Subject | Nebicapone | Small molecule | 150 mg | — |
| Background | Carbidopa | Unknown | — | — |
| Background | Levodopa | Unknown | — | — |
| Background | benserazide | Small molecule | — | — |